Cargando…
Response to Correspondence: Baricitinib: Impact on Coronavirus Disease 2019 (COVID-19) Coagulopathy? Jorgensen et al
Autores principales: | Titanji, Boghuma K, Farley, Monica M, Schinazi, Raymond F, Marconi, Vincent C |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7454400/ https://www.ncbi.nlm.nih.gov/pubmed/32797226 http://dx.doi.org/10.1093/cid/ciaa1210 |
Ejemplares similares
-
Reply to Jorgensen, et al
por: Titanji, Boghuma K, et al.
Publicado: (2020) -
Use of Baricitinib in Patients With Moderate to Severe Coronavirus Disease 2019
por: Titanji, Boghuma K, et al.
Publicado: (2020) -
Comment on: Gudu T, Stober C, Cope AP et al. Baricitinib set to join the Covid-19 therapeutic arsenal?
por: Khan, Sujoy
Publicado: (2021) -
Baricitinib in COVID-19: a coming-of-age from artificial intelligence to reducing mortality
por: Mehta, Puja, et al.
Publicado: (2022) -
Targeting Inflammation to Reduce Atherosclerotic Cardiovascular Risk in People With HIV Infection
por: Titanji, Boghuma, et al.
Publicado: (2020)